PCT Bloodwork: When to Test and How to Know You've Recovered

Most guys guess when they've recovered from a cycle. They stop their SERMs, wait a few weeks, feel "okay," and jump back on. No bloodwork, no baseline comparison, no idea whether their axis actually restarted or their testes are slowly failing.

The data says this is a coin flip at best. In the largest real-world cohort study to date (641 men), only 48.2% achieved full hormonal normalization after stopping anabolic-androgenic steroids (Grant et al., 2023). PCT improved the odds nearly fourfold, but even with it, roughly one in five men still had suboptimal testosterone at three months (Lykhonosov et al., 2020).

Bloodwork is the only way to know where you actually stand. This guide covers exactly what to order, when to draw it, and how to read the results.

How HPTA suppression works

Your hypothalamic-pituitary-testicular axis operates like a thermostat. The hypothalamus monitors circulating androgens and estrogens. When levels rise above a set point, it dials back GnRH pulses. The pituitary responds by cutting LH and FSH output. Without those signals, the testes stop producing testosterone and sperm.

Exogenous androgens hijack this system. In healthy men receiving testosterone enanthate, LH and FSH were profoundly suppressed in a dose-dependent manner, dropping to roughly 30-35% of baseline at 100 mg/week and further at higher doses (Matsumoto, 1990). The axis shuts down fast, well before most users "feel" suppressed.

Not all compounds suppress equally. Testosterone suppresses through androgen and estrogen feedback, via aromatization to estradiol, and recovery is generally predictable. 19-nor compounds like nandrolone and trenbolone add progestogenic suppression on top of androgen feedback: both compounds have significant progesterone receptor binding affinity. This produces deeper, more stubborn suppression that persists longer after clearance. SARMs suppress incompletely through partial androgen signaling, without progestogenic contribution. Clinical trials show reductions in SHBG and total testosterone but less consistent suppression of LH/FSH at studied doses, so recovery is typically faster than steroidal AAS.

The depth of suppression also scales with cycle length and polypharmacy. Grant et al. found that using four or more compounds simultaneously reduced recovery odds by 75% compared to single-compound use.

The PCT bloodwork timeline

Recovery is not a single event. It is a sequence of checkpoints, and each one tells you something different.

Pre-cycle baseline

This is your reference point. Without it, you cannot distinguish between "recovered" and "returned to an already-borderline state." A surprising number of AAS users have pre-cycle testosterone in the 300-400 ng/dL range, which would look like "recovery" on paper but is not true HPTA restoration.

Your baseline panel should include: total testosterone, free testosterone, LH, FSH, SHBG, estradiol, prolactin, HDL, LDL, triglycerides, ALT, AST, GGT, haematocrit, and haemoglobin.

Ester clearance: when to start PCT

Starting PCT too early is counterproductive. If residual ester is still releasing active compound, it continues suppressing LH and FSH while your SERMs try to stimulate them. You are fighting yourself.

These timelines are based on pharmacokinetic data. Testosterone enanthate returns to basal levels by day 9 after a single 200 mg dose (Schurmeyer & Nieschlag, 1984). Nandrolone decanoate metabolites remain detectable in 67-83% of subjects up to six months after a 150 mg dose (Bagchus et al., 2005). If you ran Deca, patience is not optional.

Mid-PCT check (4 weeks into SERM therapy)

This is your first signal that the axis is waking up. At 4-6 weeks into clomiphene or tamoxifen therapy, LH should be measurably rising (target above 2 mIU/mL as an intermediate milestone), FSH should be normalizing, and total testosterone should be trending upward.

A retrospective study of 332 hypogonadal men on clomiphene found that 73% achieved at least a 200 ng/dL increase in total testosterone, with a median assessment time of 6 weeks (Keihani et al., 2020).

If there is no LH response at 4-6 weeks, consider whether the SERM dose needs adjustment or whether you started PCT too early while residual ester was still active.

Post-PCT confirmation (4-6 weeks after last SERM dose)

This is the most important draw. SERMs artificially raise LH by blocking estrogen feedback at the pituitary. Testing while on SERMs tells you the drug is working, not that your axis has recovered. You need to confirm the HPTA is self-sustaining without pharmaceutical support.

Wait 4-6 weeks after your last SERM dose, then retest the full panel.

Long-term follow-up (3-6 months)

Even when testosterone looks normal at the post-PCT draw, Leydig cell secretory reserve may still be impaired. A 2021 study found that former AAS users (averaging 32 months post-cessation) had significantly reduced INSL3 levels, a biomarker of Leydig cell capacity, compared to controls (Rasmussen et al., 2021).

The practical implication: a normal testosterone at 3 months does not guarantee full functional recovery under physiological stress. If symptoms persist despite "normal" bloodwork, retest at 6 months. For fertility concerns, request a semen analysis; spermatogenesis takes roughly 74 days per cycle, and 90% of men recover sperm counts within 12 months (Liu et al., 2006).

The core PCT panel

Hormones

LH and FSH are the gonadotropins, and they should be the first markers to recover, confirming central axis restart. LH drives Leydig cell testosterone production; FSH drives spermatogenesis. If both remain suppressed weeks after ester clearance, the pituitary has not reactivated.

Total testosterone follows LH recovery with a lag. Expect it to trail gonadotropins by 1-3 weeks. Free testosterone is more clinically relevant than total T for assessing true recovery, especially during SERM therapy when SHBG is elevated (more on this below).

Estradiol should stay in the mid-normal male range (20-40 pg/mL) during PCT. Below 15 pg/mL suggests AI overuse; above 60 pg/mL may indicate excessive aromatization or SERM non-response.

SHBG is suppressed during AAS use (especially by orals) and rebounds during PCT, making it critical for interpreting total versus free testosterone. Prolactin matters most after 19-nor compounds: elevated prolactin above 15-20 ng/mL can independently suppress LH pulses and worsen recovery.

Lipids

AAS-induced dyslipidemia is one of the most acutely dangerous cardiovascular effects. Oral 17-alpha alkylated steroids produce the worst shifts: HDL reductions of 55% and LDL increases of 61% have been documented in bodybuilders (Hurley et al., 1984).

The HAARLEM study found that lipids returned to baseline by 3 months post-cycle in most users (Smit et al., 2022). But Hartgens et al. showed that at 6 weeks post-cessation, HDL had still not normalized after 14-week cycles (Hartgens et al., 2004).

Check a fasting lipid panel at your mid-PCT draw (4-6 weeks post-cycle). If HDL remains below 0.9 mmol/L (35 mg/dL), recheck at 12 weeks.

Liver

If you used oral hepatotoxic compounds (stanozolol, oxymetholone, methandrostenolone, superdrol), your liver panel matters. The pattern from 17-alpha alkylated steroids is bland canalicular cholestasis: elevated bilirubin with modest ALT/AST elevation (Abeles et al., 2020).

Median time to liver biochemistry normalization is 175 days from presentation (Nash et al., 2024). That is nearly 6 months. A liver panel drawn at the start of PCT may still be abnormal and requires follow-up at 3 and 6 months.

Use GGT to differentiate genuine hepatotoxicity from training-induced AST/ALT elevation. If GGT is normal while AST/ALT are mildly elevated, it is likely muscle damage, not liver injury. For more detail, see our liver enzymes on steroids guide.

Blood count

Haematocrit and haemoglobin are tied to red blood cell lifespan, roughly 120 days. Even after testosterone clears, existing red cells persist until natural senescence. A haematocrit of 52% at end-of-cycle, measured at 4 weeks post-cycle, does not indicate an ongoing problem if the trend is downward.

Track trajectory rather than a single value. Haematocrit should be declining by week 6-8 post-cessation. If it plateaus above 50%, investigate further. For context on managing elevated haematocrit, see our haemoglobin and haematocrit guide.

Compound-specific additions

The core panel covers most situations, but what you ran determines whether you need extras.

19-nor compounds (nandrolone, trenbolone)

Add prolactin to every blood draw. Nandrolone and trenbolone elevate prolactin through progestogenic activity at pituitary lactotrophs. Elevated prolactin suppresses LH pulses independently of HPG axis suppression, creating a secondary brake on recovery.

If prolactin is above 20 ng/mL at the mid-PCT draw, consider cabergoline 0.25-0.5 mg twice weekly. But note: if the compound has not fully cleared (recall nandrolone decanoate's 7-12 day half-life and months-long metabolite detection), prolactin will remain elevated regardless of dopamine agonist use.

Oral hepatotoxics

Prioritize your liver panel timing. Draw ALT, AST, GGT, and bilirubin at peak hepatotoxic exposure (4-6 weeks into the oral run) and again at 4 weeks post-cessation. Do not wait until the start of PCT to get your first liver reading; by then, the acute injury window may have passed and you will miss the peak.

Long-ester injectables

Delay your first meaningful blood draw. A test at 2 weeks post-last-injection of testosterone enanthate or nandrolone decanoate will still show drug-suppressed values. This is not recovery failure; it is pharmacokinetics. Wait the full clearance window (see the timing table above) before your first PCT panel.

Reading your PCT results: what recovery actually looks like

LH and FSH trajectories

Expect gonadotropins to lead testosterone recovery. Seeing LH and FSH enter reference range (LH: 1.7-8.6 IU/L; FSH: 1.5-12.4 IU/L) before total testosterone normalizes is a favorable sign. It means the pituitary has reactivated and is sending signals; the testes just need time to respond.

A practical staging guide:

If LH remains below 1.5 IU/L beyond 12 weeks of PCT, the pituitary has not restarted. This is a warning signal that requires clinical escalation.

The SHBG trap

This is the most counterintuitive finding in PCT bloodwork, and the most commonly missed.

Both tamoxifen and clomiphene act as estrogen agonists at the liver, directly stimulating hepatic SHBG production. Tamoxifen (20 mg/day) raises SHBG by roughly 20% while simultaneously raising total testosterone by 40% (Birzniece et al., 2010).

The problem: SHBG binds circulating testosterone. When SHBG is elevated, total testosterone can look "recovered" while free testosterone, the fraction your body actually uses, remains suppressed.

A total testosterone of 18 nmol/L (520 ng/dL) during clomiphene PCT looks like a success on paper. But with SHBG elevated to 55+ nmol/L, calculated free testosterone may be well below the normal range. This is why many men feel symptoms (low libido, fatigue, poor mood) despite "normal" bloodwork during PCT.

Lipid recovery timelines

Lipids recover faster than hormones in most cases. The HAARLEM cohort showed normalization by 3 months for injectable-only cycles. But oral-inclusive cycles may take up to 6 months, and the Hartgens data confirmed HDL was still suppressed at 6 weeks after 14-week cycles.

Anchor your expectations to what you ran:

• Injectable-only cycles: HDL and LDL recovery within 12-16 weeks
• Oral-inclusive cycles: HDL may remain suppressed for up to 6 months
• All cycles: Triglycerides normalize on a similar timeline to LDL

For a deeper dive into compound-specific lipid impacts and recovery rankings, see our cholesterol on steroids guide.

When PCT fails: the decision tree

About 20% of men with typical 6-month AAS cycles and 3 months of PCT still have suboptimal testosterone at follow-up. Knowing what pattern you are looking at determines what to do next.

Primary vs secondary hypogonadism on bloodwork

There are two failure modes, and they require different responses.

Low testosterone with low LH and FSH is secondary hypogonadism: the pituitary has not reactivated and the signal is not being sent. Start by extending your SERM course for 4-8 additional weeks. If there is no response, add HCG (250-500 IU every other day) to directly stimulate Leydig cells while continuing SERMs, then retest at 6-8 weeks.

Low testosterone with elevated or high-normal LH and FSH is primary hypogonadism: the signal is being sent, but the testes are not responding. This indicates Leydig cell damage from prolonged suppression. Start with a trial of HCG (1,000-1,500 IU three times weekly) for 4-8 weeks. If there is no response to HCG, refer to endocrinology for specialist evaluation. If testosterone remains low at 6 months post-cessation, this meets the criteria for Prolonged Post-Androgen Abuse Hypogonadism (PPAAH), a recently defined clinical entity (van Os et al., 2025), and TRT evaluation is appropriate.

When to consider TRT

If testosterone remains below 10 nmol/L (300 ng/dL) with symptoms at 6 months post-cessation despite optimized PCT, the HPTA may not fully recover. This is not rare: the Grant et al. data showed that over 36 months, more than half of AAS users did not achieve full normalization. A frank conversation with an endocrinologist about long-term testosterone replacement is warranted at this point.

The "ready for next cycle" checklist

No bloodwork threshold compensates for insufficient time. Wait a minimum of 8-12 weeks after PCT completion before retesting, and at least 4 months total from your last AAS dose. Then apply these pass/fail criteria:

Every marker must pass. Elevated haematocrit above 50% increases thromboembolic risk independently of hormonal status. HDL persistently below 1.0 mmol/L is ongoing atherogenic risk. These are not arbitrary thresholds; they are protecting you from cardiovascular consequences that persist even after hormones normalize.

Key takeaways

• Get pre-cycle bloodwork. Without a baseline, you cannot confirm true recovery.
• Wait for ester clearance before starting PCT. Starting too early wastes your SERMs.
• Test at four checkpoints: pre-cycle, mid-PCT (4 weeks), post-PCT (4-6 weeks after last SERM dose), and long-term follow-up (3-6 months).
• Order free testosterone alongside total testosterone. The SHBG trap from SERMs can make total T look recovered while free T remains suppressed.
• Add prolactin if you ran 19-nor compounds (nandrolone, trenbolone). Elevated prolactin independently brakes recovery.
• Know the two failure patterns. Low T with low LH/FSH (pituitary failure) responds to extended SERMs. Low T with high LH/FSH (testicular failure) needs HCG or specialist referral.
• Only 48% of AAS users fully normalize hormones in real-world data. PCT improves your odds nearly fourfold, but bloodwork is the only way to confirm it worked.
• All markers in the readiness checklist must pass before considering another cycle. Hormones, lipids, liver, and haematocrit each carry independent health risks.

---

References

1. Grant, B., Campbell, J., Pradeep, A., Burns, A. D., Bassett, P., Abbara, A., et al. (2023). Factors predicting normalization of reproductive hormones after cessation of anabolic-androgenic steroids in men. European Journal of Endocrinology, 189(6), 601-610. PubMed

2. Lykhonosov, M. P., Babenko, A. Y., Makarin, V. A., & Fedotov, Y. N. (2020). Peculiarity of recovery of the hypothalamic-pituitary-gonadal axis in men after using androgenic anabolic steroids. Problemy Endokrinologii, 66(1), 104-112. PubMed

3. Matsumoto, A. M. (1990). Effects of chronic testosterone administration in normal men: safety and efficacy of high dosage testosterone and parallel dose-dependent suppression of luteinizing hormone, follicle-stimulating hormone, and sperm production. Journal of Clinical Endocrinology & Metabolism, 70(1), 282-287. PubMed

4. Rahnema, C. D., Lipshultz, L. I., Crosnoe, L. E., Kovac, J. R., & Kim, E. D. (2014). Anabolic steroid-induced hypogonadism: diagnosis and treatment. Fertility and Sterility, 101(5), 1271-1279. PubMed

5. Solanki, P., Eu, B., Smith, J., Allan, C., & Lee, K. (2023). Physical, psychological and biochemical recovery from anabolic steroid-induced hypogonadism: a scoping review. Endocrine Connections, 12(12). PubMed

6. Grant, B., Kean, J., Vali, N., Campbell, J., Maden, L., Bijral, P., et al. (2023). The use of post-cycle therapy is associated with reduced withdrawal symptoms from anabolic-androgenic steroid use: a survey of 470 men. Substance Abuse: Treatment, Prevention, and Policy, 18(1), 60. PubMed

7. Liu, P. Y., Swerdloff, R. S., Christenson, P. D., Handelsman, D. J., & Wang, C. (2006). Rate, extent, and modifiers of spermatogenic recovery after hormonal male contraception. Lancet, 367(9520), 1412-1420. PubMed

8. Keihani, S., Wright, L. N., Alder, N. J., et al. (2020). Baseline gonadotropin levels and testosterone response in hypogonadal men treated with clomiphene citrate. Urology, 142, 119-124. PubMed

9. Birzniece, V., Sata, A., Sutanto, S., & Ho, K. K. Y. (2010). Neuroendocrine regulation of growth hormone and androgen axes by selective estrogen receptor modulators in healthy men. Journal of Clinical Endocrinology & Metabolism, 95(12), 5443-5448. PubMed

10. Rasmussen, J. J., Albrethsen, J., Frandsen, M. N., Jorgensen, N., Juul, A., & Kistorp, C. (2021). Serum insulin-like factor 3 levels are reduced in former androgen users, suggesting impaired Leydig cell capacity. Journal of Clinical Endocrinology and Metabolism, 106(5), e2664-e2672. PubMed

11. Schurmeyer, T., & Nieschlag, E. (1984). Comparative pharmacokinetics of testosterone enanthate and testosterone cyclohexanecarboxylate as assessed by serum and salivary testosterone levels in normal men. International Journal of Andrology, 7(3), 181-187. PubMed

12. Bagchus, W. M., Smeets, J. M., Verheul, H. A., de Jager-Van der Veen, S. M., Port, A., & Geurts, T. B. (2005). Pharmacokinetic evaluation of three different intramuscular doses of nandrolone decanoate. Journal of Clinical Endocrinology and Metabolism, 90(5), 2624-2630. PubMed

13. Hurley, B. F., Seals, D. R., Hagberg, J. M., Goldberg, A. C., Ostrove, S. M., Holloszy, J. O., et al. (1984). High-density-lipoprotein cholesterol in bodybuilders v powerlifters: negative effects of androgen use. JAMA, 252(4), 507-513. PubMed

14. Smit, D. L., Grefhorst, A., Buijs, M. M., de Hon, O., den Heijer, M., & de Ronde, W. (2022). Prospective study on blood pressure, lipid metabolism and erythrocytosis during and after androgen abuse. Andrologia, 54(4), e14372. PubMed

15. Hartgens, F., Rietjens, G., Keizer, H. A., Kuipers, H., & Wolffenbuttel, B. H. R. (2004). Effects of androgenic-anabolic steroids on apolipoproteins and lipoprotein (a). British Journal of Sports Medicine, 38(3), 253-259. PubMed

16. Abeles, R. D., Foxton, M., Khan, S., Goldin, R., Smith, B., Thursz, M. R., & Verma, S. (2020). Androgenic anabolic steroid-induced liver injury. BMJ Open Gastroenterology, 7(1), e000549. PubMed

17. Nash, A., Hunns, O., Kaur, B., Amer, A., Stroud, M., & Gordon, F. (2024). Drug-induced liver injury from selective androgen receptor modulators, anabolic-androgenic steroids and bodybuilding supplements. Alimentary Pharmacology and Therapeutics, 59(8), 953-961. PubMed

18. van Os, J., Smit, D. L., Bond, P., & de Ronde, W. (2025). Prolonged post-androgen abuse hypogonadism. Frontiers in Endocrinology, 16, 1571234. PubMed

19. Smit, D. L., Buijs, M. M., de Hon, O., den Heijer, M., & de Ronde, W. (2021). Disruption and recovery of testicular function during and after androgen abuse: the HAARLEM study. Human Reproduction, 36(4), 880-890. PubMed

20. McBride, J. A., & Coward, R. M. (2016). Recovery of spermatogenesis following testosterone replacement therapy or anabolic-androgenic steroid use. Asian Journal of Andrology, 18(3), 373-380. PubMed

21. Garevik, N., Borjesson, A., Choong, E., Ekstrom, L., & Lehtihet, M. (2016). Impact of single-dose nandrolone decanoate on gonadotropins, blood lipids and HMG CoA reductase in healthy men. Andrologia, 48(5), 595-600. PubMed